Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Retained Earnings for 18 consecutive years, with -$6.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 14.56% year-over-year to -$6.3 billion; the trailing twelve-month figure through Jun 2026 stood at -$6.3 billion (up 14.56% YoY), and the FY2025 full-year result was -$6.7 billion, up 8.03% from the prior year.
• Retained Earnings grew to -$6.3 billion in Q2 2026 per ALNY's latest filing, from -$6.5 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$5.7 billion in Q1 2022 and bottomed at -$7.4 billion in Q2 2025.
• Historically, Retained Earnings has averaged -$6.8 billion across 5 years, with a median of -$6.9 billion in 2023.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings retreated 22.82% in 2022, then climbed 14.56% in 2026.
• Over 5 years, Retained Earnings stood at -$6.6 billion in 2022, then slipped by 6.7% to -$7.0 billion in 2023, then slipped by 3.97% to -$7.3 billion in 2024, then grew by 8.03% to -$6.7 billion in 2025, then advanced by 5.53% to -$6.3 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$6.3 billion, -$6.5 billion, and -$6.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.